

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Elitek (rasburicase)

Override(s)	Approval Duration
Prior Authorization	1 course of therapy (once daily for 5 days)

Medications
Elitek (rasburicase)

APPROVAL CRITERIA

Requests for Elitek (rasburicase) may be approved if the following criteria are met:

- I. Hyperuricemia due to malignancy:
 - A. Individual is receiving chemotherapy for leukemia, lymphoma or other hematologic malignancy with risk factors for tumor lysis syndrome; **AND**
 - B. Individual is receiving treatment in a setting appropriate for providing necessary monitoring and supportive care for tumor lysis syndrome; **AND**
 - C. Individual does not have a diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency; **AND**
 - D. Individual has not received a course of Elitek therapy in the past.

Notes:

Elitek (rasburicase) has a black box warning regarding the potential to cause severe hypersensitivity (up to and including anaphylaxis), hemolysis, and methemoglobinemia. With regard to hypersensitivity reactions, hemolysis and methemoglobinemia, if any of these reactions occur; Elitek should be immediately and permanently discontinued. In addition, Elitek should not be administered in individuals with a glucose-6-phosphate dehydrogenase (G6PD) deficiency.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 10/2017.

DrugPoints® System [Internet Database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2017 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.